Hepatobiliary Cancer

  • Paul H. Sugarbaker

Part of the Cancer Treatment and Research book series (CTAR, volume 69)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Paul H. Sugarbaker, Mark A. Steves
    Pages 13-20
  3. Jane I. Tsao, Horacio J. Asbun, Kevin S. Hughes, Sabas Abaubara, David A. August, Arturo Azurin et al.
    Pages 21-31
  4. Horacio J. Asbun, Jane I. Tsao, Kevin S. Hughes
    Pages 33-41
  5. Bernard Nordlinger, Pierre Balladur
    Pages 43-51
  6. Bernard Nordlinger, Philippe Wind
    Pages 53-56
  7. Bernard Nordlinger, J.-C. Vaillant
    Pages 57-61
  8. Henri Bismuth, Laurence Chiche
    Pages 63-73
  9. Leslie H. Blumgart, Steven C. Stain
    Pages 75-96
  10. Harold J. Wanebo, Michael P. Vezeridis
    Pages 97-109
  11. Kenneth P. Ramming
    Pages 111-119
  12. James A. Knol, Frederick E. Eckhauser
    Pages 147-155
  13. Vicente Fernández-Trigo, Falah Shamsa, Joaquin Aldrete, Roland Andersson, Jean-Pierre Arnaud, Roberto Bergamaschi et al.
    Pages 185-196
  14. Steven T. Brower, Myron Schwartz, Charles Miller
    Pages 197-220
  15. W. John B. Hodgson
    Pages 221-230
  16. Bernard Langer, Paul D. Greig, Bryce R. Taylor
    Pages 231-240

About this book

Introduction

When one deals with cancer, the hepatobiliary malignancies present a chal­ lenge to the oncologists that can be characterized as a series of unsolved clinical and biological dilemmas. Liver metastases from colorectal and other gastrointestinal malignancies, hepatocellular carcinoma, cholangiocar­ cinoma, and gall bladder cancer present an array of problems but have two features in common. These are high morbidity and mortality with an overall poor result from treatment. Why is it that hepatobiliary cancer carries with it such a dismal prognosis? First of all, these diseases present, for the most part, in an advanced state. To this point in time the oncologist has had no help from early diagnosis or screening. Only the occasional patient followed by ultrasound or a tumor marker has the disease diagnosed in an asymptomatic state. By the time these diseases become symptomatic, curative treatment options have usually disappeared. Evolution has placed the liver in a protected position in order to avoid injury to the soft parenchyma. As with many other internal organs, the nerve supply is extremely limited. These two anatomic features result in a great lack of early warning signs of cancer.

Keywords

carcinoma clinical trial liver liver transplantation liver tumor metastasis morbidity mortality surgery transplantation tumor

Editors and affiliations

  • Paul H. Sugarbaker
    • 1
  1. 1.The Cancer InstituteWashington Hospital CenterUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-2604-9
  • Copyright Information Springer-Verlag US 1994
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6115-2
  • Online ISBN 978-1-4615-2604-9
  • Series Print ISSN 0927-3042
  • About this book